Encysive Plunges Over FDA Request

Encysive Pharmaceuticals (ENCY) shares lost nearly half their value by plunging $4.48 to close at $4.60. The drug researcher received a letter from the FDA requesting more clinical trial data for its pulmonary arterial hypertension treatment.